Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Mol Cell Endocrinol ; 183(1-2): 151-63, 2001 Oct 25.
Article in English | MEDLINE | ID: mdl-11604235

ABSTRACT

Milk production remains suppressed in mammals during late pregnancy despite high levels of lactogenic polypeptide hormones. At parturition, associated with a precipitous fall in circulating progesterone, rising glucocorticoid levels synergize with prolactin to initiate copious milk production. This synergy is mediated at least in part through the coordinated activation of glucocorticoid receptors and transcription factor Stat5, particularly Stat5a. Here we show that two proline-juxtaposed serine residues within the transactivation domain of Stat5a are phosphorylated in the mammary gland during late gestation and lactation, and that these phosphorylation sites inhibit the transcriptional activity of Stat5a in the absence of glucocorticoid receptor costimulation. Specifically, transfection assays revealed that phosphorylation of residues S725 and S779 of Stat5a cooperatively suppressed prolactin-stimulated transcription from the beta-casein promoter in both COS-7 kidney and MCF-7 mammary cells. This suppression was associated with shortened duration and reduced amplitude of nuclear DNA binding activity of wild type Stat5a relative to that of the serine phosphorylation-defective Stat5 mutant. However, costimulation of glucocorticoid receptors completely reversed the suppressive effect of Stat5a serine phosphorylation on beta-casein gene transcription. We propose that serine phosphorylation within the transactivation domain may limit the activity of Stat5a in the absence of proper coactivation by glucocorticoid receptors.


Subject(s)
Caseins/genetics , DNA-Binding Proteins/metabolism , Gene Expression Regulation , Mammary Glands, Animal/metabolism , Milk Proteins , Phosphoserine/metabolism , Prolactin/pharmacology , Trans-Activators/metabolism , Amino Acid Sequence , Animals , Caseins/metabolism , Cattle , Cell Line , Culture Media, Serum-Free , DNA-Binding Proteins/genetics , Female , Humans , Immunoblotting , Lactation/physiology , Mice , Mice, Inbred C57BL , Molecular Sequence Data , Phosphorylation , Pregnancy , Receptors, Glucocorticoid/metabolism , STAT5 Transcription Factor , Sequence Alignment , Trans-Activators/genetics , Tumor Cells, Cultured , Tumor Suppressor Proteins
2.
J Immunol ; 165(9): 5097-104, 2000 Nov 01.
Article in English | MEDLINE | ID: mdl-11046040

ABSTRACT

Human T cell leukemia virus type 1 (HTLV-1) transforms cytokine-dependent T lymphocytes and causes adult T cell leukemia. Janus tyrosine kinase (Jak)3 and transcription factors Stat5a and Stat5b are essential for the proliferation of normal T cells and are constitutively hyperactivated in both HTLV-1-transformed human T cell lines and lymphocytes isolated from HTLV-1-infected patients; therefore, a critical role for the Jak3-Stat5 pathway in the progression of this disease has been postulated. We recently reported that tyrphostin AG-490 selectively blocked IL-2 activation of Jak3/Stat5 and growth of murine T cell lines. Here we demonstrate that disruption of Jak3/Stat5a/b signaling with AG-490 (50 microM) blocked the proliferation of primary human T lymphocytes, but paradoxically failed to inhibit the proliferation of HTLV-1-transformed human T cell lines, HuT-102 and MT-2. Structural homologues of AG-490 also inhibited the proliferation of primary human T cells, but not HTLV-1-infected cells. Disruption of constitutive Jak3/Stat5 activation by AG-490 was demonstrated by inhibition of 1) tyrosine phosphorylation of Jak3, Stat5a (Tyr(694)), and Stat5b (Tyr(699)); 2) serine phosphorylation of Stat5a (Ser(726)) as determined by a novel phosphospecific Ab; and 3) Stat5a/b DNA binding to the Stat5-responsive beta-casein promoter. In contrast, AG-490 had no effect on DNA binding by p50/p65 components of NF-kappaB, a transcription factor activated by the HTLV-1-encoded phosphoprotein, Tax. Collectively, these data suggest that the Jak3-Stat5 pathway in HTLV-1-transformed T cells has become functionally redundant for proliferation. Reversal of this functional uncoupling may be required before Jak3/Stat5 inhibitors will be useful in the treatment of this malignancy.


Subject(s)
Cell Transformation, Neoplastic/immunology , Cell Transformation, Neoplastic/pathology , Cell Transformation, Viral/immunology , DNA-Binding Proteins/physiology , Human T-lymphotropic virus 1/immunology , Milk Proteins , Protein-Tyrosine Kinases/physiology , Signal Transduction/immunology , T-Lymphocytes/pathology , Trans-Activators/physiology , Cell Line, Transformed , Cell Transformation, Neoplastic/drug effects , DNA-Binding Proteins/antagonists & inhibitors , DNA-Binding Proteins/isolation & purification , DNA-Binding Proteins/metabolism , Enzyme Inhibitors/pharmacology , Growth Inhibitors/pharmacology , Humans , Immunosuppressive Agents/pharmacology , Interleukin-15/antagonists & inhibitors , Interleukin-15/pharmacology , Interleukin-2/antagonists & inhibitors , Interleukin-2/pharmacology , Janus Kinase 3 , Lymphocyte Activation/drug effects , NF-kappa B/metabolism , Nuclear Proteins/antagonists & inhibitors , Nuclear Proteins/metabolism , Phosphorylation/drug effects , Phytohemagglutinins/antagonists & inhibitors , Phytohemagglutinins/pharmacology , Protein-Tyrosine Kinases/antagonists & inhibitors , Protein-Tyrosine Kinases/isolation & purification , Protein-Tyrosine Kinases/metabolism , STAT5 Transcription Factor , Serine/antagonists & inhibitors , Serine/metabolism , Signal Transduction/drug effects , T-Lymphocytes/drug effects , T-Lymphocytes/enzymology , T-Lymphocytes/immunology , Trans-Activators/antagonists & inhibitors , Trans-Activators/isolation & purification , Trans-Activators/metabolism , Tumor Cells, Cultured , Tumor Suppressor Proteins , Tyrosine/antagonists & inhibitors , Tyrosine/metabolism , Tyrphostins/pharmacology
3.
Blood ; 95(12): 3816-22, 2000 Jun 15.
Article in English | MEDLINE | ID: mdl-10845915

ABSTRACT

Interleukin (IL) 4 is a potent immunomodulatory cytokine secreted by T-helper 2 (Th2) cells and Th2 mast cells that promotes the commitment of cells. However, unregulated production and release of IL-4 can exacerbate allergic reactions and increase susceptibility to infectious organisms and viruses. Here, we present evidence that AG-490, a Janus tyrosine kinase (JAK) 2-JAK3 inhibitor, effectively blocked IL-4 gene expression and secretion in the Th2 cell line D10 that was not occurring after anti-CD3 antibody stimulation, whereas AG-490 had no inhibitory effect on production of other Th2 cytokines or cytokines synthesized by the corresponding Th1 cell line clone 29. AG-490 potently inhibited IL-4-mediated proliferation of both D10 and the IL-4-dependent cell line CT.4S. Moreover, AG-490 markedly inhibited IL-4 activation of JAK3 and blocked the downstream activation of signal transducer and activator of transcription 6, as judged by tyrosine phosphorylation, DNA binding, and transcription assays. In contrast, AG-490 did not affect tumor necrosis factor alpha activation of NF-kappaB at similar concentrations of drug. These data suggest that tyrosine kinase inhibitors that inhibit JAK3 may have previously unrecognized and selective clinical potential as immunotherapeutic drugs to treat Th2-mediated diseases driven by IL-4. (Blood. 2000;95:3816-3822)


Subject(s)
Cytokines/biosynthesis , Interleukin-4/pharmacology , Protein-Tyrosine Kinases/antagonists & inhibitors , Receptors, Interleukin/biosynthesis , Th2 Cells/immunology , Tyrphostins/pharmacology , Animals , CD3 Complex/drug effects , CD3 Complex/immunology , Cell Division/drug effects , Cell Line , Enzyme Inhibitors/pharmacology , Interleukin-4/biosynthesis , Janus Kinase 3 , Kinetics , Lymphocyte Activation/drug effects , Mice , STAT6 Transcription Factor , Th2 Cells/drug effects , Th2 Cells/physiology , Trans-Activators/metabolism
4.
J Leukoc Biol ; 65(6): 891-9, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10380915

ABSTRACT

Janus kinase 3 (JAK3) is a cytoplasmic tyrosine kinase required for T cell development and activated by cytokines that utilize the interleukin-2 (IL-2) receptor common gamma chain (gamma(c)). Genetic inactivation of JAK3 is manifested as severe combined immunodeficiency disease (SCID) in humans and mice. These findings have suggested that JAK3 represents a pharmacological target to control certain lymphoid-derived diseases. Here we provide novel evidence that AG-490 potently inhibits the autokinase activity of JAK3 and tyrosine phosphorylation and DNA binding of signal transducer and activator of transcription 5a and 5b (STAT5a/b). Similar inhibitory effects were observed with other cytokines that use gamma(c). AG-490 also inhibited IL-2-mediated proliferative growth in human T cells with an IC50) = 25 microM that was partially recoverable. Moreover, we demonstrate that this inhibitor prevented tetanus toxoid antigen-specific T cell proliferation and expansion but failed to block activation of Zap70 or p56Lck after anti-CD3 stimulation of human T cells. Taken together, these findings suggest that AG-490 inhibits the JAK3-mediated Type II signaling pathway but not the T cell receptor-derived Type I pathway and possesses therapeutic potential for T cell-derived pathologies such as graft-versus-host disease, allergy, and autoimmune disorders.


Subject(s)
Cytokines/pharmacology , Enzyme Inhibitors/pharmacology , Protein-Tyrosine Kinases/physiology , T-Lymphocytes/immunology , Transcription Factors/physiology , Tyrphostins/pharmacology , Animals , Antigens/physiology , Cell Division/drug effects , DNA-Binding Proteins/antagonists & inhibitors , Humans , Interleukin-2/antagonists & inhibitors , Janus Kinase 3 , Lymphocyte Activation/immunology , Mice , Phosphorylation/drug effects , Protein-Tyrosine Kinases/antagonists & inhibitors , Protein-Tyrosine Kinases/metabolism , Signal Transduction , T-Lymphocytes/cytology
5.
J Biol Chem ; 274(21): 14699-705, 1999 May 21.
Article in English | MEDLINE | ID: mdl-10329665

ABSTRACT

Cytokines and hormones activate a network of intracellular signaling pathways to regulate cell division, survival and differentiation. In parallel, a series of growth inhibitory mechanisms critically restrict cell population sizes. For example, mitogens can be opposed in crowded cell cultures through contact-inhibition or by autocrine release of antiproliferative substances. Here, we characterize a small, heat-stable growth inhibitor secreted by a rat T lymphoma line when cultured at high cell density. Short term incubation (<60 min) of prolactin-responsive Nb2 lymphoma cells at high density selectively blocked prolactin stimulation of p42/p44 mitogen-activated protein kinases and transcription factors Stat1 and Stat3 but not prolactin activation of Stat5 or the tyrosine kinase Jak2. The selective effects of cell density on prolactin signaling were reversible. Furthermore, exposure of cells at low density to conditioned media from cells incubated at high density had the same inhibitory effects on prolactin signaling. This selective inhibition of discrete prolactin signals was mimicked by short term preincubation of cells at low density with staurosporine or genistein but not with bis-indoleyl maleimide, cyclic nucleotide analogs, calcium ionophore A23187, or phorbol 12-myristate 13-acetate. A heat-stable, proteinase K-resistant, low molecular weight factor with these characteristics was recovered from high density culture medium. The partially purified inhibitor suppressed Nb2 cell growth with a sigmoidal concentration response consistent with a saturable, receptor-mediated process.


Subject(s)
Growth Inhibitors/physiology , Mitogen-Activated Protein Kinases , Prolactin/physiology , Signal Transduction/physiology , Animals , Calcium-Calmodulin-Dependent Protein Kinases/physiology , Cell Count , Cell Division , Culture Media, Conditioned , DNA-Binding Proteins/physiology , Genistein/pharmacology , Lymphoma, T-Cell , Mitogen-Activated Protein Kinase 3 , Rats , STAT1 Transcription Factor , STAT3 Transcription Factor , Staurosporine/pharmacology , Trans-Activators/physiology , Tumor Cells, Cultured
6.
J Immunol ; 162(7): 3897-904, 1999 Apr 01.
Article in English | MEDLINE | ID: mdl-10201908

ABSTRACT

AG-490 is a member of the tyrphostin family of tyrosine kinase inhibitors. While AG-490 has been considered to be a Janus kinase (JAK)2-specific inhibitor, these conclusions were primarily drawn from acute lymphoblastic leukemia cells that lack readily detectable levels of JAK3. In the present study, evidence is provided that clearly demonstrates AG-490 potently suppresses IL-2-induced T cell proliferation, a non-JAK2-dependent signal, in a dose-dependent manner in T cell lines D10 and CTLL-2. AG-490 blocked JAK3 activation and phosphorylation of its downstream counterpart substrates, STATs. Inhibition of JAK3 by AG-490 also compromised the Shc/Ras/Raf/mitogen-activated protein kinase (MAPK) signaling pathways as measured by phosphorylation of Shc and extracellular signal-related kinase 1 and 2 (ERK1/2). AG-490 effectively inhibited tyrosine phosphorylation and DNA binding activities of several transcription factors including STAT1, -3, -5a, and -5b and activating protein-1 (AP-1) as judged by Western blot analysis and electrophoretic mobility shift assay. These data suggest that AG-490 is a potent inhibitor of the JAK3/STAT, JAK3/AP-1, and JAK3/MAPK pathways and their cellular consequences. Taken together, these findings support the notion that AG-490 possesses previously unrecognized clinical potential as an immunotherapeutic drug due to its inhibitory effects on T cell-derived signaling pathways.


Subject(s)
Adaptor Proteins, Signal Transducing , Adaptor Proteins, Vesicular Transport , Calcium-Calmodulin-Dependent Protein Kinases/metabolism , DNA-Binding Proteins/metabolism , Milk Proteins , Protein-Tyrosine Kinases/metabolism , Signal Transduction/immunology , T-Lymphocytes/drug effects , T-Lymphocytes/enzymology , Trans-Activators/metabolism , Tyrphostins/pharmacology , Binding Sites/drug effects , Binding Sites/immunology , Cell Line , DNA/metabolism , DNA-Binding Proteins/antagonists & inhibitors , Enzyme Activation/drug effects , Enzyme Activation/immunology , Enzyme Inhibitors/pharmacology , Interleukin-2/antagonists & inhibitors , Interleukin-2/pharmacology , Janus Kinase 3 , Lymphocyte Activation/drug effects , Phosphorylation/drug effects , Phosphotyrosine/metabolism , Protein-Tyrosine Kinases/antagonists & inhibitors , Proteins/metabolism , RNA, Messenger/metabolism , Receptors, Interleukin-2/biosynthesis , STAT1 Transcription Factor , STAT3 Transcription Factor , STAT5 Transcription Factor , Shc Signaling Adaptor Proteins , Signal Transduction/drug effects , T-Lymphocytes/immunology , Trans-Activators/antagonists & inhibitors
7.
J Biol Chem ; 273(46): 30218-24, 1998 Nov 13.
Article in English | MEDLINE | ID: mdl-9804779

ABSTRACT

Transcription factors of the Stat family are controlled by protein kinases. Phosphorylation of a positionally conserved tyrosine residue is obligatory for Stat dimerization, nuclear translocation, and specific DNA binding. Studies of Stat1 and Stat3 have suggested that serine phosphorylation may also regulate function. We now identify serine residues located in a conserved PSP motif of Stat5a (Ser725) and Stat5b (Ser730) as major phosphorylation sites, using mutagenesis, phosphoamino acid analysis, and site-specific anti-Stat5-phosphoserine antibodies. Unexpectedly, phosphorylation control of this PSP motif differed between the highly homologous Stat5a and Stat5b proteins. Whereas Ser725 of Stat5a was constitutively phosphorylated both in COS-7 cells and Nb2 lymphocytes, phosphorylation of Ser730 of Stat5b was markedly stimulated by prolactin. The data also suggested the existence of a second major serine phosphorylation site in Stat5a. Interestingly, constitutive phosphorylation of the PSP motif was suppressed by PD98059 but not by staurosporine under conditions in which both agents inhibited mitogen-activated protein kinases. Furthermore, pretreatment of cells with staurosporine, PD98059, H7, or wortmannin did not prevent either Stat5a or Stat5b from becoming maximally serine-phosphorylated after prolactin exposure. We propose that two pathways regulate Stat5 serine phosphorylation, one that is prolactin-activated and PD98059-resistant and one that is constitutively active and PD98059-sensitive and preferentially targets Stat5a. Finally, phosphorylation of the PSP motif of Stat5a or Stat5b was not essential for DNA binding or transcriptional activation of a beta-casein reporter gene in COS-7 cells, suggesting that serine kinase control of Stat5 activity differs from that of Stat1 and Stat3.


Subject(s)
DNA-Binding Proteins/metabolism , Milk Proteins , Prolactin/pharmacology , Proline/metabolism , Serine/metabolism , Trans-Activators/metabolism , Alanine/metabolism , Amino Acid Sequence , Amino Acid Substitution , Animals , COS Cells , Caseins/genetics , Caseins/metabolism , DNA/metabolism , Genes, Reporter , Molecular Sequence Data , Phosphoamino Acids/metabolism , Phosphorylation , STAT5 Transcription Factor , Structure-Activity Relationship , Transcriptional Activation/drug effects
8.
Vet Immunol Immunopathol ; 63(1-2): 27-36, 1998 May 15.
Article in English | MEDLINE | ID: mdl-9656438

ABSTRACT

Cytokines, hormones and hematopoietic growth factors transduce biological signals across the cell membrane via a highly conserved family of single membrane-spanning receptors. The intracellular signal transducing machinery responsible for mediating these responses has remained largely unknown. However, recent identification of a homologous class of tyrosine kinases, Janus Kinases (JAKs), and a related family of transcription factors, signal transducers and activators of transcription (STATs), has shed new light on the molecular mechanisms responsible for mediating hematopoietin signaling and immune response. Current research efforts within the field of cytokine signaling have now shifted to understanding how these molecules are activated by hematopoietic receptors, positively and negatively regulated by kinases and phosphatases, and how they impact on gene transcription to ultimately coordinate cell homeostasis, proliferation and differentiation. This article will review some of our results identifying the involvement of JAKs, STATs, and secondary effector molecules activated following engagement of hematopoietic receptors for IL-2, IL-4, and prolactin. Here, we provide evidence for the ingenious ability of cytokine receptors to selectively recruit and activate these proteins among a repertoire of possible alternative biochemical messengers as a means to affect unique and general cell responses.


Subject(s)
Cytokines/physiology , Hematopoietic Cell Growth Factors/physiology , Signal Transduction/physiology , Animals , DNA-Binding Proteins/physiology , Humans , Interleukin-2/physiology , Interleukin-4/physiology , Models, Biological , Prolactin/physiology , Protein-Tyrosine Kinases/physiology , Receptors, Cytokine/physiology , Trans-Activators/physiology
9.
Proc Natl Acad Sci U S A ; 95(1): 126-31, 1998 Jan 06.
Article in English | MEDLINE | ID: mdl-9419340

ABSTRACT

The activation of Janus kinases (JAKs) is crucial for propagation of the proliferative response initiated by many cytokines. The proliferation of various cell lines, particularly those of hematopoietic origin, is also modulated by mediators of oxidative stress such as nitric oxide and thiol redox reagents. Herein we demonstrate that nitric oxide and other thiol oxidants can inhibit the autokinase activity of rat JAK2 in vitro, presumably through oxidation of crucial dithiols to disulfides within JAK2. The reduced form of JAK2 is the most active form, and the oxidized JAK2 form is inactive. Nitric oxide pretreatment of quiescent Ba/F3 cells also inhibits the interleukin 3-triggered in vivo activation of JAK2, a phenomenon that correlates with inhibited proliferation. Furthermore, we observed that the autokinase activity of JAK3 responds in a similar fashion to thiol redox reagents in vitro and to nitric oxide donors in vivo. We suggest that the thiol redox regulation of JAKs may partially explain the generally immunosuppressive effects of nitric oxide and of other thiol oxidants.


Subject(s)
Nitric Oxide/pharmacology , Protein-Tyrosine Kinases/metabolism , Proto-Oncogene Proteins , Sulfhydryl Reagents/pharmacology , Animals , Baculoviridae , Cells, Cultured , Dithiothreitol/pharmacology , Enzyme Activation , Enzyme Inhibitors/pharmacology , Humans , Iodobenzoates/pharmacology , Janus Kinase 1 , Janus Kinase 2 , Janus Kinase 3 , Mice , Oxidation-Reduction , Rats , Spodoptera
10.
J Biol Chem ; 272(24): 15459-65, 1997 Jun 13.
Article in English | MEDLINE | ID: mdl-9182578

ABSTRACT

Many cytokines, hormones, and growth factors activate Janus kinases to tyrosine phosphorylate select members of the Stat transcription factors. For full transcriptional activation, Stat1 and Stat3 also require phosphorylation of a conserved serine residue within a mitogen-activated protein kinase phosphorylation consensus site. On the other hand, two recently identified and highly homologous Stat5a and Stat5b proteins lack this putative mitogen-activated protein kinase phosphorylation site. The present study set out to establish whether Stat5a and Stat5b are under the control of an interleukin-2 (IL2)-activated Stat5 serine kinase. We now report that IL2 stimulated marked phosphorylation of serine and tyrosine residues of both Stat5a and Stat5b in human T lymphocytes and in several IL2-responsive lymphocytic cell lines. No Stat5a/b phosphothreonine was detected. Phosphoamino acid analysis also revealed that Stat5a/b phosphotyrosine levels were maximized within 1-5 min of IL2 stimulation, whereas serine phosphorylation kinetics were slower. Interestingly, IL2-induced serine phosphorylation of Stat5a differed quantitatively and temporally from that of Stat5b with Stat5a serine phosphorylation leveling off after 10 min and the more pronounced Stat5b response continuing to rise for at least 60 min of IL2 stimulation. Furthermore, we identified two discrete domains of IL2 receptor beta (IL2Rbeta) that could independently restore the ability of a truncated IL2Rbeta mutant to mediate Stat5a/b phosphorylation and DNA binding to the gamma-activated site of the beta-casein gene promoter. These observations demonstrated that there is no strict requirement for one particular IL2Rbeta region for Stat5 phosphorylation. Finally, we established that the IL2-activated Stat5a/b serine kinase is insensitive to several selective inhibitors of known IL2-stimulated kinases including MEK1/MEK2 (PD98059), mTOR (rapamycin), and phosphatidylinositol 3-kinase (wortmannin) as determined by phosphoamino acid and DNA binding analysis, thus suggesting that a yet-to-be-identified serine kinase mediates Stat5a/b activation.


Subject(s)
Androstadienes/pharmacology , Flavonoids/pharmacology , Interleukin-2/pharmacology , Polyenes/pharmacology , Protein Serine-Threonine Kinases/metabolism , Receptors, Interleukin-2/physiology , Animals , Cells, Cultured , DNA-Binding Proteins/metabolism , Enzyme Activation , Enzyme Inhibitors/pharmacology , Humans , Kinetics , Phosphorylation , Protein Serine-Threonine Kinases/antagonists & inhibitors , Rats , Serine/metabolism , Sirolimus , Tumor Cells, Cultured , Tyrosine/metabolism , Wortmannin
11.
Mol Cell Endocrinol ; 117(2): 131-40, 1996 Mar 25.
Article in English | MEDLINE | ID: mdl-8737372

ABSTRACT

The present study of prolactin (PRL) receptor-mediated recruitment of signal transducers and activators of transcription (STATs) demonstrates that PRL activates STAT3, in addition to STAT1 and STAT5 as previously reported, and that STAT1, STAT3 and STAT5 are mediators of PRL effects in cells whether of lymphoid, myeloid or mammary epithelial origin. Furthermore, receptor mutants M240 and T280 that do not mediate PRL-induced JAK2 activation and cell proliferation, are also unable to mediate STAT activation, supporting the proposed model of JAK2 as the initial effector protein used by PRL receptors. On the other hand, tyrosine phosphorylation analysis and electrophoretic mobility shift assays showed that receptor mutant G328, which lacks four of the five conserved cytoplasmic tyrosine residues of PRL receptors, retained the ability to activate JAK2 and STAT1, STAT3 and STAT5. These results support the notion that phosphotyrosyl residues other than those of the receptor, i.e., JAK2, are involved in recruiting STAT proteins to the activated PRL receptor complex.


Subject(s)
DNA-Binding Proteins/metabolism , Milk Proteins , Prolactin/metabolism , Receptors, Prolactin/metabolism , Trans-Activators/metabolism , Tyrosine/metabolism , Animals , Base Sequence , Humans , Mice , Molecular Sequence Data , Oligonucleotide Probes , Phosphorylation , Rats , Receptors, IgG/genetics , Receptors, IgG/metabolism , Receptors, Prolactin/genetics , STAT1 Transcription Factor , STAT3 Transcription Factor , STAT5 Transcription Factor , Sequence Deletion , Sheep , Time Factors , Tumor Cells, Cultured
12.
Endocrinology ; 136(8): 3512-8, 1995 Aug.
Article in English | MEDLINE | ID: mdl-7628388

ABSTRACT

Identification of the signal transduction pathways used by PRL is essential for understanding the role of PRL receptors in growth and differentiation processes. Early cellular mediators of PRL receptor activation include tyrosine kinases of the Janus kinase (JAK) and SRC families, with rapid nuclear signaling via tyrosine phosphorylated signal transducers and activators of transcription. In the present study we provide the first demonstration of PRL-induced activation of Ras, an oncogenic protein that supports an alternative signaling route from the membrane to the nucleus. PRL stimulated Ras in rat Nb2-SP lymphoma cells, as detected by a 2.0-fold increase in the GTP-bound state of the molecule (P < 0.01). This activation was associated with marked tyrosine phosphorylation and increased membrane association of the 52-kilodalton form of SHC. Moreover, PRL induced binding of SHC to growth factor receptor bound 2 and the guanine-nucleotide exchange factor son of sevenless, a common method used by growth factor receptors to activate Ras. In contrast, no apparent regulation by PRL of Ras via VAV or p120 Ras-guanosine triphosphatase-activating protein was detected, based upon an absence of PRL-inducible tyrosine phosphorylation of these proteins. Collectively, these results provide a molecular bridge between activation of PRL receptor-associated tyrosine kinases and subsequent stimulation of the serine/threonine kinase Raf-1, an established Ras target that was recently shown to be activated by PRL in Nb2 cells. We conclude that PRL is able to activate Ras via recruitment of the signaling proteins SHC, growth factor receptor bound 2, and son of sevenless in Nb2 cells. Moreover, PRL induced tyrosine phosphorylation of SHC in two of three PRL-responsive human breast cancer cell lines, suggesting that SHC-mediated Ras activation is a commonly used signaling strategy by PRL.


Subject(s)
Adaptor Proteins, Signal Transducing , Gene Expression Regulation/drug effects , Genes, ras/drug effects , Membrane Proteins/physiology , Prolactin/pharmacology , Proteins/physiology , Animals , GRB2 Adaptor Protein , Humans , Protein Sorting Signals/physiology , Rats , Sheep , Son of Sevenless Proteins , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...